# Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

> **NCT03203642** · PHASE2 · COMPLETED · sponsor: **Kadmon, a Sanofi Company** · enrollment: 80 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney
- ADPKD

## Interventions

- **DRUG:** Tesevatinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03203642
- **Lead sponsor:** Kadmon, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-12
- **Primary completion:** 2022-01-25
- **Final completion:** 2022-01-25
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03203642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03203642, "Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03203642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*